WeVote
Log In

Bill

Bill

S 3538

Establishes "Equitable Drug Pricing and Patient Access Act."

2024-2025 Regular Session Introduced by Vin Gopal and 3 co-sponsors

New Jersey bill proposes regulating drug pricing and expanding patient medication access through state-level mechanisms, addressing affordability concerns while risking industry opposition and federal legal challenges.

Introduced in the Senate, Referred to Senate Health, Human Services and Senior Citizens Committee
#healthinsur #medicaid #pharmaceutic
0
WeVote Research Nonpartisan
Bill Summary · S 3538

Legislative bill overview

S 3538 would establish New Jersey's "Equitable Drug Pricing and Patient Access Act," though the bill text itself is not publicly detailed in available records. Based on the title, it appears designed to address pharmaceutical pricing and ensure patient access to medications, likely through regulatory mechanisms or negotiation frameworks specific to New Jersey.

Why is this important

Drug pricing is a persistent public health concern, with many New Jersey residents struggling to afford medications. Any state-level intervention on this issue directly affects healthcare affordability and could serve as a model for other states navigating federal pharmaceutical regulations while protecting patient access.

Potential points of contention

  • Pharmaceutical industry opposition: Drug manufacturers typically resist state-level price controls, arguing they undermine research and development investment
  • Regulatory scope and enforcement: Unclear whether the bill would apply only to state programs, all insurers, or individual pharmacies, creating potential implementation complexity
  • Federal preemption concerns: Pharmaceutical regulation is primarily federal; New Jersey's authority to impose pricing restrictions may face legal challenges

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.